About Us Careers Contact Us

Home
Products
Isotope Labeled Active Pharmaceutical Ingredients (APIs)
Selumetinib-[d4]

Inquiry List

* Name:
* Phone:
* Service & Products of Interested: [Isotope Labeled Active Pharmaceutical Ingredients (APIs)] Selumetinib-[d4]
Project Description:
* Quantity
* Email:
* Organization We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
* Verification Code:

Our Highlights

Optimal Prices
Buying products on this site guarantees the best price
Flexible Batches
Flexible batch size to meet different needs of global customers
Prompt Delivery
Warehouses in multiple cities to ensure timely delivery
Quality Assurance
Strict process parameter control to ensure product quality
One-to-one Customization
One-to-one custom synthesis for special structural needs

Application Area

Environmental

Stable isotope-labeled compounds are used as environmental pollutant standards for the detection of air, water, soil, sediment and food.

Clinical diagnostic

In addition to treating various diseases, isotopes are used for imaging, diagnosis, and newborn screening.

Organic Chemistry

Small molecule compounds labeled with stable isotopes can be used as chemical reference for chemical identification, qualitative, quantitative, detection, etc. Various types of NMR solvents can be used to study the structure, reaction mechanism and reaction kinetics of compounds.

Metabolic Research

Stable isotope labeling allows researchers to study metabolic pathways in vivo in a safe manner.

Selumetinib-[d4]

Inquiry

General Information
Catalog: BLP-004220
Molecular Formula: C17H11D4BrClFN4O3
Molecular Weight: 461.71

Chemical Structure

Description	Isotopic labelled Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, and so may inhibit cellular proliferation in MEK-overexpressing tumor cells. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various tumor cell types, and are drivers of diverse cellular activities, including cellular proliferation. Check for active clinical trials or closed clinical trials using this agent.
Related CAS	606143-52-6 (unlabelled)
Purity	>98%